Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Oral Dose of 30 mg BAY 1753011 Given as IR Tablet in Male and Female Participants in a Multicenter, Non-randomized, Non-controlled, Non-blinded Study With Group Stratification in Participants With Renal Impairment and Control Group Matched for Age-, Gender-, and Weight
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Pecavaptan (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 03 Nov 2022 New trial record